Because B12 is water-soluble, extra is excreted rather than stored long term
Make sure the tip of the needle is in the liquid
Herbilabs supplies bacteriostatic water strictly for Research Use Only (RUO)
Book An Appointment Today Booking an appointment with Exclusive Med Aesthetics is effortless and convenient

BPC-157 Dosing in Hepatic Impairment: Evidence, Risks, and Clinical Guidance At a glance No FDA-approved formulation / BPC-157 is available only through 503A compounding pharmacies Zero published human RCTs evaluating BPC-157 in hepatic impairment populations Animal models show hepatoprotective effects against NSAID, alcohol, and toxin-induced liver damage Standard compounded dose range is 200-500 mcg/day subcutaneously or intramuscularly Suggested starting dose in hepatic impairment is 200-250 mcg/day subcutaneously Peptides are cleared primarily by proteolytic degradation, not hepatic CYP450 metabolism Liver enzyme monitoring (ALT, AST, bilirubin) recommended at baseline and every 2-4 weeks BPC-157 has shown cytoprotective effects on gastric and intestinal mucosa in over 20 animal studies The FDA has not established hepatic dosing adjustments for BPC-157 Cycle length in liver-compromised patients: 4-6 weeks with reassessment before continuation What Is BPC-157 and How Does It Work

A minimum of 98% is considered research grade, though 99% is strongly preferred for sensitive assays, cell culture experiments, and in vivo pre-clinical studies where compound purity directly affects reproducibility and result accuracy